Ireland· IE-PA-EU/1/22/1631/001
Breyanzi 1.1-70 x 10^6 cells/mL/1.1-70 x 10^6 cells/mL dispersion for infusion
A antineoplastic agents product containing lisocabtagene maraleucel, registered in Ireland by Celgene Europe B.V.. The same ATC class is registered in 6 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Lisocabtagene maraleucel is registered in 6 of 19 countries.
Countries holding a registration under ATC L01 (antineoplastic agents), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 3 of them publish a price we can compare per daily dose
Lisocabtagene maraleucel · ATC L01
6 / 19 countries
- Canada
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
The record
At a glance
HPRA (Ireland)- Active substance
- Lisocabtagene Maraleucel
- Manufacturer
- Celgene Europe B.V.
- Country
- Ireland (IE)
- ATC code
- L01
- ATC class
- ANTINEOPLASTIC AGENTS
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/22/1631/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lisocabtagene maraleucel in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsBreyanzi >= 5.1 x 10^6 cellen [CD4 component], suspensie voor injectieCelgene Europe B.V.
- CanadaBREYANZIBRISTOL-MYERS SQUIBB CANADA
- CzechiaBREYANZIBristol-Myers Squibb Pharma EEIG, Dublin
- SpainBREYANZI 1,1-70 × 10E6 CELULAS/ML / 1,1-70 × 10E6 CELULAS/ML DISPERSION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FinlandBreyanziBristol-Myers Squibb Pharma EEIG
- FranceBREYANZI 1,1 à 70 × 1 000 000 cellules/ml / 1,1 à 70 × 1 000 000 cellules/ml, dispersion pour perfusionBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- United KingdomBreyanzi 1.1million-70million cells/ml / 1.1million-70million cells/ml dispersion for infusion vialsBristol-Myers Squibb Pharmaceuticals Ltd
- IcelandBreyanziBristol-Myers Squibb Pharma EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Breyanzi
- Liechtenstein · Breyanzi
- Norway · Breyanzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/79c5c062-d796-49ff-a5ab-ba91a386212e GET /v1/drugs/79c5c062-d796-49ff-a5ab-ba91a386212e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dispersion for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L01"
],
"strength": null,
"pa_number": "EU/1/22/1631/001",
"substances": [
"Lisocabtagene Maraleucel"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "04/04/2022",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about lisocabtagene maraleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.